Adverse reactions to inactivated COVID-19 vaccination in patients with chronic liver disease: The effect of anxiety

Li Lv, Xiao-Qing Lin, Yan Chen, He-Dan Chen, Mei-Xian Zhang, Hui Shao, Tao-Hsin Tung, and Jian-Sheng Zhu

Department of Infectious Diseases, Taizhou Hospital, Zhejiang University, Linhai, Zhejiang, China; Department of Infectious Diseases, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, Zhejiang, China; Evidence-based Medicine Center, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, Zhejiang, China

ABSTRACT
Studies have shown that patients with chronic liver disease are at a higher risk of contracting novel coronavirus pneumonia than healthy individuals, and many guidelines state that patients with chronic liver disease should be prioritized for COVID-19 vaccination, but there are a few studies on its safety in CLD patients. We aimed to evaluate the safety of the inactivated COVID-19 vaccine in patients with chronic liver disease, and the effect of anxiety on adverse reactions. A questionnaire survey for self-administered post-vaccination adverse reaction monitoring was conducted from June 17, 2021, to August 11, 2021, in patients with chronic liver disease attending a tertiary care hospital in Taizhou, China. We analyzed the data from a total of 160 participants who scanned the QR code on social media to respond to the questionnaire. The overall incidence of adverse reactions after COVID-19 vaccination in patients with chronic liver disease was 44.4% (71/160), and the most common adverse reaction was local injection site reaction, accounting for 80.3% of adverse reactions (57/71). No serious adverse reactions were reported. Approximately 53.1% of the patients had anxiety about vaccination, and 51.8% of those who felt anxious reported adverse reactions. The safety of COVID-19 vaccination in patients with chronic liver disease is good, and there is a strong association between adverse reactions and vaccine anxiety. Pre-vaccination education for patients with vaccine anxiety and psychological counseling may reduce reports of adverse reactions and improve patients’ confidence in the vaccine.

Introduction
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is a novel coronavirus that causes Coronavirus Disease 2019 (COVID-19). The latest data published by the World Health Organization (WHO) shows that as of December 22, 2021, more than 275 million confirmed cases of COVID-19 have been diagnosed worldwide, and more than 5.36 million patients have died from COVID-19.

Chronic liver disease is a high-risk factor for SARS-CoV-2 pneumonia infection, and patients with chronic liver disease have a higher mortality rate than healthy individuals when infected with SARS-CoV-2.

COVID-19 vaccination is an important method for effective prevention of SARS-CoV-2 infection, pneumonia, hospitalization, and death, and for reducing the risk of transmission, and is particularly recommended for patients with chronic disease.

There are a few safety studies related to the COVID-19 vaccine in patients with chronic liver disease, and some studies suggest that the COVID-19 vaccine is safe and effective in patients with nonalcoholic fatty liver disease. The rates of infection, as well as post-infection mortality rates, were also reduced after COVID-19 vaccination was administered to patients with cirrhosis.

Through this study, we aimed to discuss the adverse effects of inactivated COVID-19 vaccine in patients with CLD and the effect of anxiety on the adverse effects.

Methods
We conducted an anonymous cross-sectional survey using the WeChat-incorporated Wen-Juan-Xing (Ranxing Information Technology Co., Ltd., Changsha, Hunan, China), the largest online survey platform in China. Our target population was patients with liver disease who were already vaccinated with inactivated COVID-19 vaccine, who presented to a tertiary care hospital in Taizhou, China. We included patients with chronic liver disease combined with certain other diseases (hypertension, hyperlipidemia, diabetes, etc.), but we excluded cancer patients. When patients visited the liver disease clinic from June 17, 2021, to August 11, 2021, they scanned a QR code and answered a self-administered questionnaire about COVID-19 vaccinations. In the questionnaire, we...
first investigated their knowledge, attitudes, and behaviors; then, all those who had had COVID-19 vaccinations recalled whether they experienced any local or systemic adverse reactions after vaccination.

This study was exempted from informed consent and was approved by the Ethics Committee of Taizhou Hospital, Zhejiang Province, China (approval number: k20210217). All procedures were performed in accordance with the guidelines of our institutional ethics committee and adhered to the principles of the Declaration of Helsinki. All participants’ personal information was provided anonymously.

We designed our questionnaire based on the instruction manuals of the inactivated COVID-19 vaccines manufactured by Sinovac after consulting preventive experts about gathering valid feedback on adverse reactions after vaccination. The content of the questionnaire was as follows: (1) basic information such as age, sex, education level, occupation, and place of residence; (2) Any anxiety about COVID-19 vaccination; We asked about their level of anxiety about vaccination and defined anxiety as very anxious, anxious, not anxious, very not anxious; (3) history of vaccination, such as the history of vaccine allergy; (4) the type of chronic liver disease (such as hepatitis B, fatty liver, and cirrhosis), treatment status, and whether other chronic diseases, such as hypertension and diabetes, were comorbid; (5) local and systemic adverse reactions (including Pain, Inflammation, Redness, Swelling, or Itch, Fatigue, dizziness, dizziness, muscle pain, or fever) after COVID-19 vaccination and their extent; According to the grading criteria for adverse events of vaccine issued by the State Drug Administration of China, we define Grade 1 as mild adverse reactions that can resolve on their own; Grade 2 and 3 as moderate adverse reactions that require outpatient medical attention; and Grade 4 as serious adverse reactions that require inpatient treatment.

The primary objective of the investigation was to determine any self-reported adverse reactions to the COVID-19 vaccine experienced by these patients, and whether these reactions were correlated with vaccine anxiety. Our vaccine safety assessment included all patients with chronic liver disease who had received the COVID-19 vaccine and was indicated by the severity and number of reported local or systemic adverse reactions to COVID-19 vaccination.

Responses to questions such as those regarding the participants’ basic information, and knowledge attitudes toward the vaccine, were categorized and expressed as counts and percentages. Factors potentially affecting adverse reactions to the COVID-19 vaccine, such as sex, age, work, knowledge, and anxiety, and attitude, were tested using chi-square tests. To further analyze whether groups of people who developed adverse reactions after vaccination were significantly influenced by anxiety, we stratified the different groups and analyzed the effect of anxiety on adverse reactions using chi-square tests.

In univariate analysis, variables with $P < .05$, were included in the model. All data were analyzed using IBM SPSS Statistics software (version 26.0; SPSS Inc., Chicago, IL, USA). We identified a $P$-value $< .05$, as a statistically significant difference in the study population.

### Results

We collected a total of 325 questionnaires, and after excluding oncology patients and incomplete questionnaires, 160 questionnaires were included in the analysis. The response rate was 49.2%. The response data for sex, age, occupation category, place of residence, Anxiety about vaccination, and type of chronic liver disease are shown in Table 1.

In our study, we described the nature, incidence and severity of adverse reactions reported by the survey participants. Most adverse reactions were mild and self-limiting. Of the 71 patients that reported the adverse reactions, 70 were mild. Only one patient presented to the outpatient clinic for management. No serious adverse reactions were observed.

It is shown in the Table 2 that patients who had anxiety ($\chi^2 = 4.012, p = .045$) reported significantly more adverse reactions after inactivated SARS-CoV-2 vaccination and the type and status of a patient’s liver disease, age, and the presence of other comorbid chronic diseases, had no significant effect on the reporting of adverse reactions.

Table 3 shows the relationship between adverse reactions and anxiety in the survey participants. The following groups were more likely to have adverse reactions due to anxiety: males ($\chi^2 = 4.226, p = .040$), education level of senior

### Table 1. Baseline characteristics of patients with chronic liver disease and cardiac analysis of factors associated with adverse effects, $N = 160$. |
| Variables                                | Category          | $N$ (%) |
|------------------------------------------|-------------------|---------|
| Total                                    |                   | 160     |
| Sex                                      | Male              | 102     | 63.8% |
|                                           | Female            | 58      | 36.3% |
| Age (years)                              | $\leq 60$         | 139     | 86.9% |
|                                           | $> 60$            | 21      | 13.1% |
| Residence                                | Rural             | 106     | 66.3% |
|                                           | City              | 54      | 33.8% |
| Occupation                               | Farmer            | 58      | 36.3% |
|                                           | Non-Farmer        | 102     | 63.8% |
| Education level                          | Junior Secondary  | 78      | 48.8% |
|                                           | and below         |         |       |
|                                           | Senior Secondary  | 30      | 18.8% |
|                                           | and above         | 52      | 32.5% |
| Anxiety                                  | Yes               | 85      | 53.1% |
|                                           | No                | 75      | 46.9% |
| Hepatitis B                              | Yes               | 102     | 63.8% |
|                                           | No                | 58      | 36.3% |
| Nonalcoholic fatty liver disease         | Yes               | 57      | 35.6% |
|                                           | No                | 103     | 64.4% |
| Other Liver Diseases                     | Yes               | 34      | 21.3% |
|                                           | No                | 126     | 78.8% |
| Liver cirrhosis                          | No                | 142     | 88.8% |
|                                           | Yes               | 18      | 11.3% |
| Comorbidity                              | No comorbidity    | 96      | 60.0% |
|                                           | One comorbidity   | 40      | 25.0% |
|                                           | More than one comorbidity | 24 | 15.0% |
| Hypertension                             | Yes               | 30      | 18.8% |
|                                           | No                | 130     | 81.3% |
| Hyperlipidemia                           | Yes               | 25      | 15.6% |
|                                           | No                | 135     | 84.4% |
| Diabetes                                 | Yes               | 16      | 10.0% |
|                                           | No                | 144     | 90.0% |
| Hyperuricemia                            | Yes               | 9       | 5.6%  |
|                                           | No                | 151     | 94.4% |
| Respiratory diseases                     | Yes               | 5       | 3.0%  |
|                                           | No                | 152     | 95.0% |
| Kidney disease                           | Yes               | 2       | 1.3%  |
|                                           | No                | 158     | 98.8% |
| Treatment                                | Yes               | 82      | 51.3% |
|                                           | No                | 78      | 48.8% |
| Allergic reaction                        | No                | 146     | 91.3% |
|                                           | Yes               | 14      | 8.8%  |
Table 2. Univariate analysis of factors associated with adverse reactions of COVID-19 vaccine. N = 160.

| Variables                        | Category                   | No adverse reactions | Incidence of adverse reactions | χ²   | P    |
|----------------------------------|-----------------------------|----------------------|--------------------------------|------|------|
| Total                            |                             | **89**               | **71**                         | **4.226**| **0.045**|
| Sex                              | Male                        | 58                   | 44                             | 0.175 | 0.676 |
|                                  | Female                      | 31                   | 27                             | 0.493 | 0.462 |
| Age (years)                      | ≤60                         | 76                   | 63                             | 0.386 | 0.534 |
|                                  | >60                         | 13                   | 8                              | 0.044 | 0.836 |
| Residence                        | Rural                       | 61                   | 45                             | 0.45  | 0.51  |
|                                  | City                        | 28                   | 26                             | 0.044 | 0.836 |
| Occupation                       | Farmer                      | 38                   | 20                             | 3.607 | 0.058 |
|                                  | Non-Farmer                  | 51                   | 51                             | 0.331 | 0.565 |
| Education level                  | Junior Secondary and below  | 49                   | 29                             | 3.59  | 0.166 |
|                                  | Senior Secondary            | 16                   | 14                             | 0.036 | 0.853 |
|                                  | Junior College and above    | 24                   | 17                             | 5.556 | 0.012 |
| Anxiety                          | Yes                         | 41                   | 44                             | 4.012 | 0.045 |
|                                  | No                          | 48                   | 27                             | 0.360 | 0.552 |
| Hepatitis B                      | Yes                         | 55                   | 47                             | 0.331 | 0.565 |
|                                  | No                          | 34                   | 24                             | 0.41  | 0.52  |
| Nonalcoholic fatty liver disease | Yes                         | 36                   | 21                             | 2.036 | 0.154 |
|                                  | No                          | 53                   | 50                             | 0.552 | 0.012 |
| Other Liver Diseases             | Yes                         | 17                   | 17                             | 0.552 | 0.012 |
|                                  | No                          | 72                   | 54                             | 0.209 | 0.162 |
| Liver cirrhosis                  | Yes                         | 81                   | 61                             | 1.027 | 0.311 |
|                                  | No                          | 8                    | 10                             | 0.552 | 0.012 |
| Comorbidity                      | No comorbidity              | 50                   | 46                             | 4.769 | 0.032 |
|                                  | One comorbidity             | 28                   | 12                             | 3.072 | 0.045 |
|                                  | More than one comorbidity   | 11                   | 13                             | 1.951 | 0.162 |
| Treatment                        | Yes                         | 50                   | 32                             | 0.982 | 0.321 |
|                                  | No                          | 39                   | 39                             | 0.126 | 0.721 |
| Allergic reaction                | No                          | 82                   | 64                             | 0.197 | 0.657 |
|                                  | Yes                         | 7                    | 7                              | 0.080 | 0.776 |

Table 3. Relationship between adverse reactions to inactivated COVID-19 vaccine and anxiety in different populations, N = 160.

| Population stratification       | Anxious | Incidence of adverse reactions | χ²   | P    |
|---------------------------------|---------|--------------------------------|------|------|
| Sex                             | Male    | 28                             | 16   | 4.226 | **0.040**|
|                                  | Female  | 16                             | 11   | 0.341 | 0.559 |
| Age (years)                     | ≤60     | 71                             | 68   | 1.780 | 0.182 |
|                                  | >60     | 14                             | 7    | 3.387 | 0.076 |
| Residence                       | Rural   | 30                             | 15   | 2.153 | 0.142 |
|                                  | City    | 14                             | 12   | 2.597 | 0.107 |
| Education level                 | Junior Secondary and below  | 20                             | 9    | 1.462 | 0.227 |
|                                  | Senior Secondary and above  | 24                             | 18   | 4.040 | **0.044**|
| Hepatitis B                     | Yes     | 29                             | 18   | 4.774 | **0.029**|
|                                  | No      | 32                             | 20   | 0.102 | 0.750 |
| Nonalcoholic fatty liver disease| Yes     | 12                             | 5    | 2.982 | 0.098 |
|                                  | No      | 37                             | 24   | 3.127 | 0.077 |
| Other Liver Diseases            | Yes     | 7                              | 3    | 0.748 | 0.387 |
|                                  | No      | 18                             | 7    | 1.580 | 0.209 |
| Liver cirrhosis                 | Yes     | 26                             | 20   | 3.301 | 0.069 |
|                                  | No      | 23                             | 9    | 10.045| **0.002**|
| Comorbidity                     | Yes     | 21                             | 17   | 0.209 | 0.648 |
|                                  | No      | 5                              | 2    | 1.167 | 0.280 |
| Allergic reaction               | Yes     | 39                             | 25   | 3.072 | **0.080**|
|                                  | No      | 5                              | 2    | 1.167 | 0.280 |

secondary and above ($\chi^2 = 4.040$, $p = 0.044$), hepatitis B ($\chi^2 = 4.774$, $p = 0.029$), undergoing treatment ($\chi^2 = 10.045$, $p = 0.002$), and previous allergic reactions ($\chi^2 = 3.072$, $p = 0.080$). However, age, residence, presence of other types of liver disease besides hepatitis B, and presence of other comorbidities ($p > 0.05$) did not have a significant effect.

It is shown in the Table 4 that we did a multiple logistic regression analysis of factors associated with anxiety and found that no factors had significant effect on anxiety. ($p > 0.05$)

**Discussion**

Many people are concerned about studies of COVID-19 vaccination in patients with chronic liver disease. The safety of COVID-19 vaccination in patients with chronic liver disease is good, with the incidence of minor adverse reactions ranging from 24.9% to 90%. The most common adverse reactions are local injection site reactions, fatigue, headache, exhaustion, and muscle pain, which are usually mild and self-limiting.
We studied the adverse reactions to COVID-19 vaccination reported by 160 patients with chronic liver disease and found that the overall incidence of adverse reactions in patients with chronic liver disease was 44.4% (71/160), of which 80.3% (57/71) were local injection reactions; that most of the adverse reactions were mild and resolved spontaneously; and that no severe adverse reactions occurred.

Our analysis of factors influencing adverse reactions to COVID-19 vaccination in patients with chronic liver disease suggests that age and anxiety were important factors influencing adverse reaction reports. In our study by chi-square analysis, we found no significant effect of other comorbidities on adverse vaccine reactions in patients with liver disease, which may be related to the sample size as well as population differences. Interestingly, a higher percentage of patients with chronic liver disease had anxiety about the COVID-19 vaccine, compared to other patients with chronic diseases, which in turn was significantly correlated with the rate of adverse reaction reports. Among the patients we surveyed, 53.1% (n = 85/160) had vaccine anxiety. In turn, 51.8% (44/85) of the patients with anxiety reported adverse reactions, which was significantly higher than the 36.0% of patients without anxiety (P = .045). In this study, men, high school education and above, patients with hepatitis B, and those undergoing treatment for liver disease, were more likely to have more reports of adverse reactions due to anxiety. We did a multiple logistic regression analysis of the factors affecting anxiety and found that none of them were significant. Maybe anxiety is inherent in the population, which is independent of other influencing factors.

Anxiety is a common health issue worldwide. Many countries have reported adverse reactions to vaccinations (such as headache, dizziness, and fatigue), as a result of group anxiety, which were confirmed to be unrelated to the vaccine itself in subsequent investigations by medical personnel. The WHO defines this type of adverse reactions as immunization anxiety-related adverse reactions.

A number of studies have observed anxiety-related adverse events after immunization, involving vaccines such as tetanus, tetanus diphtheria, hepatitis B, human papillomavirus, and influenza A vaccine (Table 5). In a COVID-19 vaccine study, 64 cases of anxiety-related adverse reactions were reported in the United States, mostly presenting with dizziness or headache. Researchers in Italy also reported 339 cases of anxiety-related adverse reactions after COVID-19 vaccination, accounting for 24% of the adverse reactions. In addition, anxiety-related adverse reactions to the Japanese encephalitis vaccine, measles vaccine, and cervical cancer vaccine have all been reported in the literature. In 2015, the WHO Global Advisory Committee on Vaccine Safety convened an expert working group to discuss "Adverse reactions due to immunization anxiety," which was updated to "Immunization stress related reactions." In a slight departure from their working group discussion, we included anxiety about the vaccine as a potential factor in the occurrence of adverse reactions, and found that patient anxiety about the vaccine was associated with reports of adverse effects of the vaccine. It has been shown that we can reduce patients’ anxiety about vaccines and reduce vaccine anxiety-related adverse reactions by increasing patient awareness through better education and increasing patients’ confidence in vaccines.

Our study has some limitations. First, direct questioning was used to ascertain whether anxiety was present, and no scale was used to assess the degree of anxiety, which may not provide a comprehensive understanding of anxiety. Second, the patients’ adverse effects were self-reported and may have been biased. Third, the possibility that the nature of the questionnaire being retrospective could be a limitation. The reason

Table 4. Multiple logistic regression analysis of factors associated with anxiety. N = 160.

| Variables | Categories | P      | OR (95%CI) |
|-----------|------------|--------|------------|
| Sex       | Male vs. Female | 0.735  | 0.579–2.171 |
| Education level | Senior Secondary and above vs. Junior Secondary and below | 0.056  | 0.985–3.554 |
| Hepatitis B| Yes vs. No   | 0.666  | 0.445–3.554 |
| Treatment  | Yes vs. No   | 0.805  | 0.418–3.080 |
| Allergic reaction | Yes vs. No | 0.999  | 0 |

Table 5. The relationship between adverse reactions to inactivated COVID-19 vaccine and anxiety in different populations.

| Author         | Study design | Study period | Study sample | Setting | Vaccine | Content | Reference |
|----------------|--------------|--------------|--------------|---------|---------|---------|-----------|
| Anne M.et al.  | Cross-sectional study | 2021 | America | COVID-19 | Sixty-four cases of anxiety-related adverse reactions were reported, with dizziness or headache in 36 cases (56%), pallor and excessive sweating in 20 cases (31%), nausea and vomiting in 16 cases (25%), and hypotension in 10 cases (16%) Anxiety accounted for 24% of the 1704 adverse reactions | 15 |
| Vincenza et al. | Cross-sectional study | 2021 | Total: 314664 | Italy | COVID-19 | Anxiety related adverse reactions | 16 |
| Tiffany A. et al. | Review | 2017 | Total: 120 | America | HPV. et al | Seven articles reported anxiety-related adverse reactions. The most frequently reported adverse reactions were syncope, dizziness, fatigue, headache, and tic disorder or involuntary movements | 13 |
| Awnish K. et al. | Review | 2017 | Total: 1037 | India | JE, DTP et al | Anxiety-related adverse reactions were reported in 175 (17%) articles. Of these, 95 (54%) articles reported anxiety-related reactions to the Japanese encephalitis (JE) vaccine and 56 (32%) articles reported anxiety-related reactions to the measles vaccine | 17 |
being, patients recalling previous vaccine adverse reactions, and reporting current feelings of anxiety about the vaccine, could indicate that for some patients, experiencing adverse reactions causes anxiety about the vaccine – and perhaps not the other way around. Fourth, the possibility that the group of patients attending the hospital who chose to complete the questionnaire may have been biased toward those that experienced anxiety toward vaccines, and/or those that had experienced adverse reactions. Fifth, we collected questionnaires in the hospital, lacking blank controls for the healthy population. Last, our study was conducted on patients with chronic liver disease in one hospital, making it difficult to reflect the characteristics of all patients with chronic liver disease.

Conclusion

Our study shows that the COVID-19 vaccine has a good safety profile in patients with chronic liver disease, and that there is a strong correlation between reported adverse reactions and vaccine anxiety. Therefore, it is beneficial to reduce anxiety-induced adverse reactions through education and psychological guidance to increase the confidence of patients with chronic liver disease in the COVID-19 vaccine.

Acknowledgments

We would like to thank the participants for their cooperation and support.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

This paper did not receive any funding.

ORCID

Li Lv http://orcid.org/0000-0002-2132-6558

Author contributions

J.S. Z. and T.H.T. conceived the study. M.X.Z., J.S. Z. and T.H.T. designed the questionnaire. J.S. Z. and H. S. collected the data. X.Q. L. was responsible for coding the analyses. L.L. and X.Q.L. analysed and interpreted the data and wrote the first draft of the paper. Y.C. and H.D.C. searched, and interpreted the relevant literature. All authors edited and approved the final manuscript.

References

1. Wu Q, Dudley MZ, Chen X, Bai X, Dong K, Zhuang T, Salmon D, Yu H. Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Med. 2021;19(1):173. doi:10.1186/s12116-021-02059-5.
2. Albillos A, Lario M, Alvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 2014;61(6):1385–96. doi:10.1016/j.jhep.2014.08.010.
3. Marjot T, Moon AM, Cook JA, Abd-Elsalam S, Aloman C, Armstrong MJ, Pose E, Brenner EJ, Cargill T, Catana MA, Dhanasekaran R. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. J Hepatol. 2021;74(3):567–77. doi:10.1016/j.jhep.2020.09.024.
4. Kochhar S, Salmon DA. Planning for COVID-19 vaccines safety surveillance. Vaccine. 2020;38(40):6194–98. doi:10.1016/j.vaccine.2020.07.013.
5. Stefan M, Dlouhy P, Bezdickeva L. [Vaccination against COVID-19]. Klin Mikrobiol Infekc Lek. 2021;27:49–60.
6. Sharma A, Patnaik I, Kumar A, Gupta R. COVID-19 vaccines in patients with chronic liver disease. J Clin Exp Hepatol. 2021;11(6):720–26. doi:10.1016/j.jceh.2021.06.013.
7. Wang J, Hou Z, Liu J, Gu Y, Wu Y, Chen Z, Ji J, Diao S, Qiu Y, Zou S, Zhang A. Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): a multicenter study. J Hepatol. 2021;75(2):439–41. doi:10.1016/j.jhep.2021.04.026.
8. John BV, Deng Y, Scheinberg A, Mahmoud N, Taddei TH, Kaplan D, Labrada M, Baracco G, Dahman B. Association of BNT162b2 mRNA and mRNA-1273 vaccines with COVID-19 infection and hospitalization among patients with cirrhosis. JAMA Intern Med. 2021;181(10):1306–14. doi:10.1001/jamainternmed.2021.4325.
9. Fix OK, Blumberg EA, Chang KM, Chu J, Chung RT, Goacher EK, Hamid J, Kaul DK, Kulik LM, Kwo DR, RM, et al. American association for the study of liver diseases expert panel consensus statement: vaccines to prevent coronavirus disease 2019 infection in patients with liver disease. Hepatology. 2021;74(2):1049–64. doi:10.1002/hep.31751.
10. Thuluvath PJ, Bobarts P, Chauhan M. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases. J Hepatol. 2021;75(6):1434–39. doi:10.1016/j.jhep.2021.08.008.
11. Cornberg M, Buti M, Eberhardt CS, Grossi PA, Shouval D. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. J Hepatol. 2021;74(4):944–51. doi:10.1016/j.jhep.2021.01.032.
12. Asadi-Pooya AA, Barzegar Z, Sadeghian S, Nezafat A, Shahasavandi M, Nabaviyadeh SA. COVID-19 vaccine hesitancy among patients with epilepsy or other chronic conditions. Disaster Med Public Health Prep. 2021;1–3. doi:10.1017/dmp.2021.311.
13. Suragh TA, Lamprianou S, MacDonald NE, Loharikar AR, Balakrishnan MR, Benes O, Hyde TB, McNeil MM. Cluster anxiety-related adverse events following immunization (AEFI): an assessment of reports detected in social media and those identified using an online search engine. Vaccine. 2018;36(40):5949–54. doi:10.1016/j.vaccine.2018.08.064.
14. Loharikar A, Suragh TA, MacDonald NE, Loharikar A, Suragh TA, MacDonald NE, Balakrishnan MR, Benes O, Lamprianou S, Hyde TB, et al. Anxiety-related adverse events following immunization (AEFI): a systematic review of published clusters of illness. Vaccine. 2018;36(2):299–305. doi:10.1016/j.vaccine.2017.11.017.
15. Hause AM, Gee J, Johnson T, Jazwa A, Marquez P, Miller E, Su J, Shimabukuro TT, Shay DK. Anxiety-related adverse event clusters after Janssen COVID-19 vaccination - five U.S. mass vaccination sites, April 2021. MMWR Morb Mortal Wkly Rep. 2021;70(18):685–88. doi:10.15585/mmwr.mm7018e3.
16. Gianfredi V, Minerva M, Casu G, Capraro M, Chicca G, Gaetti G, Mazzocchi RM, Musarò P, Basteri P, Bertini B, et al. Immediate adverse events following COVID-19 immunization: A cross-sectional study of 31,664 Italian subjects. Acta Biomed. 2021;92(S6):e20212487. doi:10.23750/ab.20212487.12365.
17. Singh AK, Wagner AL, Joshi J, Carlson BF, Aneja S, Boulton ML. Causality assessment of serious and severe adverse events following immunization in India: a 4-year practical experience. Expert Rev Vaccines. 2018;17(6):555–62. doi:10.1080/14760584.2018.1484285.
18. McMurtry CM. Managing immunization stress-related response: a contributor to sustaining trust in vaccines. Can Commun Dis Rep. 2020;46(6):210–18. doi:10.4745/ccdr.v46i06a10.